E-selectin - PDFSEARCH.IO - Document Search Engine

E-selectin
Results: 51

#	Item
1	#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2014-04-10 23:45:38
2	E-selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers of Medicine/Division of Hematology Oncology, University of Michigan, Ann Arbor, MI;2Section of Vas Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-12 15:21:52
3	GMI-1271, a Novel E-Selectin Antagonist, Combined with Induction Chemotherapy in Elderly Patients with Untreated AML Daniel J. DeAngelo1, Brian A. Jonas2, Dale L. Bixby3, Pamela S. Becker4, Michael E. O’Dwyer5, Anjali Add to Reading List Source URL: glycomimetics.com Language: English* - Date: 2017-06-01 12:20:20
4	ADMINISTRATION OF THE DUAL E-SELECTIN/CXCR4 ANTAGONIST, GMI-1359, RESULTS IN A UNIQUE PROFILE OF TUMOR MOBILIZATION FROM THE BONE MARROW AND FACILITATION OF CHEMOTHERAPY IN A MURINE MODEL OF FLT3 ITD AML Abstract # 2826 Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-12 15:21:24
5	The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2 Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-12 15:22:04
6 $A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan$	A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-05 13:18:26
7 $GMI-1271, a Potent E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML: A Novel, Well-Tolerated Regimen with a High Remission Rate Daniel J. DeAngelo*1, Brian A. Jonas2, Jane L. Liesveld3,$	GMI-1271, a Potent E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML: A Novel, Well-Tolerated Regimen with a High Remission Rate Daniel J. DeAngelo1, Brian A. Jonas2, Jane L. Liesveld3, Add to Reading List Source URL: glycomimetics.com Language: English* - Date: 2017-06-26 08:58:58
8	Inhibition of E-Selectin or E-selectin together with CXCR4 Re-sensitizes Multiple Myeloma to Treatment Barbara Muz 1, Ph.D. Henna Bazai1, Anita Sekula1, William Fogler2 , Ted Smith2, John Magnani2 and Abdel Kareem Azab1 Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2017-04-05 12:37:24
9	COMBINATION OF A GLYCOMIMETIC ANTAGONIST TO E-SELECTIN AND CXCR4, GMI-1359, WITH AN ANTI-PD-L1 ANTIBODY ATTENUATES REGULATORY T CELL INFILTRATION AND ACCELERATES TIME TO COMPLETE RESPONSE IN THE MURINE CT26 TUMOR MODEL W Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-11-14 10:12:52
10	AANovel NovelSmall SmallMolecule MoleculeE-Selectin E-SelectinInhibitor InhibitorGMI-1271 Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2013-01-17 07:02:12